Bristol Myers Squibb takes its CAR-T patent case to US' top court in bid to revive $1.2B verdict against Gilead

Bristol Myers Squibb takes its CAR-T patent case to US' top court in bid to revive $1.2B verdict against Gilead

Source: 
Fierce Pharma
snippet: 

The high-stakes patent war between CAR-T giants Gilead Sciences and Bristol Myers Squibb isn’t over just yet. After an appeals court overturned a $1.2 billion verdict against Gilead, BMS is asking the United States’ top court to take another look.